ReviewCurrent rheumatology reports2004
Scleroderma renal crisis: new insights and developments.
Review in Current rheumatology reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 31 citations in OpenAlex.
- Scleroderma renal crisis with posterior reversible encephalopathy syndrome.Archives of medical science : AMS · 2023Article
- Mistaken identity: normotensive scleroderma renal crisis.BMJ case reports · 2014Article
- A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis.PloS one · 2012Article
- The pathogenesis of systemic sclerosis revisited.Clinical reviews in allergy & immunology · 2011Review
- Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis.Journal of cellular and molecular medicine · 2010Review
- Scleroderma renal crisis: a pathology perspective.International journal of rheumatology · 2010Article
- The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.Clinical rheumatology · 2008Article
- [Clinical risk-adapted therapies in systemic sclerosis].Zeitschrift fur Rheumatologie · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scleroderma renal crisis (SRC) was once a uniformly fatal complication of systemic sclerosis (SSc). With the introduction of angiotensin-converting enzyme inhibitors as treatment, outcomes have improved significantly, though 39% to 50% of SSc patients who develop SRC continue to have poor outcomes, including permanent dialysis and death. Early recognition and treatment with angiotensin-converting enzyme inhibitors are important in the effective management of SRC, though given the continuing morbidity and mortality caused by SRC, they are clearly not sufficient. Newer therapies based on the pathophysiologic mechanisms underlying the development and perpetuation of SRC are needed. This article reviews the epidemiology, pathogenesis, risk factors, clinical features, and treatment of SRC, with an emphasis on recent insights and developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.